. Author manuscript; available in PMC: 2020 Feb 1.

Published in final edited form as: Muscle Nerve. 2018 Nov 26;59(2):201–207. doi: 10.1002/mus.26335

Table 1.

Baseline Characteristics.

Item	Rasagiline Treated	Rasagiline Controls	Historical Controls^41,42	p-value^*
Number participants	60	20	177
Number female (%)	20 (33%)	7 (35%)	65 (37%)	0.89
Number bulbar onset (%)	10 (17%)	3 (15%)	44 (25%)	0.29
Number taking riluzole (%)	49 (82%)	16 (80%)	121 (68%)	<.001
Mean age in years (SD/range)	58.4 (10.2 / 28–75)	57.5 (8.5 / 40–73)	57.3 (11.0 / 30–80)	0.22
Mean symptom duration years (SD/range)	1.23 (0.49 / 0.43–2.04)	1.37 (0.46 / 0.52–2.05)	1.06 (0.46 / 0.23–2.0)	0.004
Mean baseline % predicted vital capacity (SD/range)	92.5 (12.3 / 73–122)	94.4 (12.5 / 75–124)	94.9 (15.3 / 75–178)	0.52
Mean baseline ALSFRS-R (SD/range)	38.2 (6.1 / 17–48)	35.9 (7.5 / 14–45)	38.7 (4.8 / 23–47)	0.08

P-value for 3 way ANOVA comparing treated, controls, and historical controls.